MedTrace Logo

Study of Biological Markers in Children With Sickle Cell Disease

NCT04839159 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2021-04-09

No results posted yet for this study

Summary

Sickle cell disease is associated with significant morbi-mortality hence the interest in an early and targeted care. At present, there is no plasmatic marker able to identify infants at higher risk of developping severe complications later in life. However, recent studies have demonstrated a correlation between certain complications of the disease and biomarkers of the endothelial dysfunction characterizing it.

Investigators prospectively followed a cohort of children diagnosed with SCD through the universal neonatal screening using inflammatory and haemostatic plasmatic markers to study their annual evolution. Investigators then will evaluate potential associations between these biological markers and the occurrence of SCD related complications. A secondary objective of this study is to evaluate the repercussions of therapeutic intervention on these markers.

.

Conditions

Interventions

OTHER

Blood sampling

Blood sampling at the age of 6 and 12 months, 2-3-4 years

OTHER

Blood sampling

Blood sampling before any new sickle cell disease treatment as determined by a physician according to the standard of care to which the hospital adheres

Sponsors & Collaborators

  • Queen Fabiola Children's University Hospital

    lead OTHER

Principal Investigators

  • Bushra Zucca, MD · Queen Fabiola Children's University Hospital

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-05-10
Primary Completion
2021-06-30
Completion
2021-06-30

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04839159 on ClinicalTrials.gov